The German Asthma Net: Anti-IL5(R) therapy reduces disease burden in a real-life severe asthma cohort in comparison to patients on maintenance OCS therapy

348 of 2283 patients with severe asthma>12 yrs. included in the real-life, long-term German Asthma Net registry used anti-IL5(R) antibody therapy (mepolizumab, benralizumab, reslizumab), (57±13 yrs., 57% female, BMI 27±6 kg/m², 5±5 exacerbations per year, ACQ score 2.6±1.5), compared to 329 corticosteroid (OCS) dependent patients (49±17 yrs., 55% female, BMI 27±6 kg/m², 4±4 exac./year, ACQ 2.6±1.4).

Abb. 1  

Baseline ACQ, mAQLQ and FEV1 values were comparable, patients on IL5(R) received more OCS at baseline (6±11 vs 4±10 mg, p=0.021). In comparison to systemic corticosteroid dependent patients without biological therapy, patients on anti-IL5(R) therapy showed significantly better asthma control (ACQ-5 score), better quality of life (mAQLQ score), and an increase in FEV1 in% predicted (all mean+SD). OCS dependency (median [IQR]) was also significantly reduced:

Conclusion Real-life, severe asthma patients treated with anti-IL5(R) biologics showed long-term benefits regarding pivotal outcome and disease control parameters including asthma control, quality of life, lung function, and corticosteroid use, highlighting beneficial effects previously documented in controlled studies in a real-life severe asthma cohort. These effects appear to be superior to those obtained with OCS treatment.

Publikationsverlauf

Artikel online veröffentlicht:
09. März 2023